Published in Arthritis Rheum on February 01, 2010
Spectrum of Eosinophilic End-Organ Manifestations. Immunol Allergy Clin North Am (2015) 0.89
Cardiac involvement of churg-strauss syndrome as a reversible cause of dilated cardiomyopathy. J Cardiovasc Ultrasound (2015) 0.83
Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Res Ther (2011) 0.83
Magnetic resonance imaging of the cardiac manifestations of Churg-Strauss. JRSM Open (2014) 0.79
Standard and feature tracking magnetic resonance evidence of myocardial involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegener's) in patients with normal electrocardiograms and transthoracic echocardiography. Int J Cardiovasc Imaging (2012) 0.78
Cardiac involvement as the main presenting feature in eosinophilic granulomatosis with polyangiitis. BMJ Case Rep (2013) 0.78
Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol (2012) 0.77
Detecting cardiac involvement with magnetic resonance in patients with active eosinophilic granulomatosis with polyangiitis. Int J Cardiovasc Imaging (2016) 0.76
Coronary involvement in Churg-Strauss syndrome. Indian Heart J (2015) 0.75
T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides. J Cardiovasc Magn Reson (2017) 0.75
A Cardiac Graft from a Donor with Granulomatosis with Polyangiitis-A Case Report. Thorac Cardiovasc Surg Rep (2016) 0.75
Coronary periarteritis in a patient with multi-organ IgG4-related disease. J Radiol Case Rep (2015) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
Sudden cardiac death caused by coronary vasculitis. Virchows Arch (2012) 0.75
Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int (2016) 0.75
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA (2011) 8.83
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med (2010) 8.64
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 7.30
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension (2005) 5.05
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 3.61
Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension (2007) 3.57
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens (2002) 3.43
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Telomere length and possible link to X chromosome. Lancet (2004) 3.36
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome. J Am Coll Cardiol (2013) 3.12
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncol (2006) 2.88
Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol (2012) 2.80
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol (2012) 2.56
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol (2010) 2.51
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens (2005) 2.47
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28
Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens (2007) 2.26
Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension (2006) 2.19
Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns. Am J Hypertens (2013) 2.08
Predictive role of the nighttime blood pressure. Hypertension (2010) 2.07
Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail (2009) 2.03
Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension (2012) 2.03
Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisited. Environ Health Perspect (2002) 2.03
Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension (2014) 1.97
Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A (2007) 1.92
Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension (2011) 1.89
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens (2004) 1.87
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell (2011) 1.84
Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens (2003) 1.83
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res (2005) 1.79
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens (2003) 1.78
Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol (2012) 1.77
On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med (2007) 1.75
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med (2011) 1.74
Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens (2003) 1.74
Myocyte apoptosis in heart failure. Cardiovasc Res (2005) 1.71
Host and environmental determinants of heart rate and heart rate variability in four European populations. J Hypertens (2003) 1.70
Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum (2004) 1.70
Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension (2009) 1.69
Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol (2002) 1.68
Eligibility for renal denervation: experience at 11 European expert centers. Hypertension (2014) 1.68
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med (2008) 1.65
Acute viral myocarditis. Eur Heart J (2008) 1.65
An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gbeta3 C825T polymorphism. J Hypertens (2003) 1.64
Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res (2009) 1.63
The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Press Monit (2007) 1.62